Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01389102 · ClinicalTrials.gov registry record · Phase 3
Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms
A Phase 3 study, sponsored by Lumara Health.
- Completed
- Registry status
- Phase 3
- Development phase
- 454
- Enrollment target
NCT01389102 is a Phase 3 study that has completed, run by Lumara Health. The registered enrollment target is 454 participants.
The verdict
NCT01389102, a Phase 3 study, has completed, sponsored by Lumara Health.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 454 participants
- Enrollment target
Study Summary
Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
Interventions
- DRUG Estradiol transdermal one 90 μL spray
- DRUG Estradiol transdermal spray, two 90 μL sprays
- DRUG Estradiol transdermal three 90 μL sprays
- DRUG Placebo transdermal two 90 μL sprays
- DRUG Placebo transdermal three 90 μL sprays
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 454 participants |
| Start Date | 2004-12 |
| Est. Completion | 2006-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01389102
The ClinicalTrials.gov registry entry for NCT01389102 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 454 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumara Health, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Estradiol transdermal one 90 μL spray is the first listed.
NCT01389102 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01389102 about?
NCT01389102 is a clinical study titled "Estradiol Transdermal Spray in the Treatment of Vasomotor Symptoms". Estradiol treatment is effective at reducing vasomotor symptoms (eg hot flushes) in postmenopausal women. This study will evaluate the safety and efficacy of Evamist.
What is the current status of trial NCT01389102?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 454 participants. The study started on 2004-12. Estimated completion is 2006-11.
What interventions are being tested in trial NCT01389102?
The interventions under investigation include: Estradiol transdermal one 90 μL spray (DRUG), Estradiol transdermal spray, two 90 μL sprays (DRUG), Estradiol transdermal three 90 μL sprays (DRUG), Placebo transdermal two 90 μL sprays (DRUG), Placebo transdermal three 90 μL sprays (DRUG).
Who is sponsoring clinical trial NCT01389102?
This trial is sponsored by Lumara Health, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.